New combo therapy may simplify steroid diabetes care
NCT ID NCT07117240
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether a combination of a GLP-1 drug (lixisenatide) plus long-acting insulin works better than standard intensive insulin therapy for people whose diabetes is caused by steroid medications. About 100 adults with conditions like asthma or arthritis who need long-term steroids will be enrolled. The goal is to see if the combo approach improves blood sugar control and reduces the need for extra insulin shots.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lixisenatide plus insulin glargine
What this could lead to
If this works, it could offer a simpler, more effective way to manage steroid-induced diabetes with fewer injections and better blood sugar control.
What could go wrong
This is a small, early-phase trial with only 100 participants, so results may not apply to everyone. The combination therapy may not prove superior or could cause side effects like nausea or low blood sugar.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Warsaw Medical University
Warsaw, Warsaw, 02-097, Poland